← All trials
NCT04460651
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 14, 2020
- Primary completion
- Jan 31, 2021
- Completion date
- Jan 31, 2021
- First posted
- Jul 7, 2020
- Last posted
- Nov 23, 2020
- Enrollment
- 2000
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Estudios Clínicos Latino AméricaLead sponsor
- AmarinCollaborator
- Estudios Clínicos Latino AméricaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.